AMT and Parkinson disease: After dosage optimization, 15 μM low dosage α-MT was selected and we showed that this dosage significantly protected against mutant G2019S-induced DA degeneration (DA neuron loss, PD phenotype and late-stage decrease in DA content) (Fig. 3A–D).